Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Oncology Clinical Trials and Drug Development

ONS member Moe Schwartz, PharmD, BCOP, professor of pharmacy practice in the James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio and member of the Cincinnati Tri-State ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cancer drug…

Oct 16^th • 38 mins listen